Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial

November 7, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal infections, today announced that an independent Safety Review Committee has approved the continuation of dose escalation in its ongoing proof-of-concept trial for BSG005. Following a favorable review of safety data from the first cohort, a new cohort of five patients will soon begin treatment at an increased dose level.“We are encouraged by the Safety Review Committee’s positive review of BSG005’s safety profile in the initial cohort, and we look forward to

Presentation of the interim report January - September 2024 on November 15

GARO will publish its report for the third quarter 2024 at 08.30 CET on November 15.   Conference call at 9.30 CET The company will host a conference call at 9.30 CET the same day. The conference will be hosted by Patrik Andersson, President & CEO and Helena Claesson, Chief Financial Officer.   Dial in numbers: Sweden: +46 (0)20 089 0141International: +44 (0)207 107 06 13   The presentation material will be published at www.garo.se prior to the conference call. The conference will also be audio webcasted in “listen-only” mode at the GARO website www.garo.

Himalaya Shipping Ltd. (HSHP) Announces its Preliminary Results for the Three and Nine Months Ended September 30, 2024

Hamilton, Bermuda, November 7, 2024   Himalaya Shipping Ltd. (“Himalaya,” “Himalaya Shipping” or the “Company”) announces preliminary unaudited results for the three and nine months ended September 30, 2024.     Highlights for the Third Quarter of 2024   •          Total operating revenues of $39.2 million, which is an average time charter equivalent (“TCE”) earnings of approximately $36,800 per day, gross[1].  Average Baltic 5TC Capesize Index was $24,909 per day. •          Net income of $10.7 million and Adjusted EBITDA[2] of $31.0 million for the third quarter of

Rejlers achieves validation of Science-Based Targets, advancing commitment to net-zero emissions by 2050

Rejlers is proudly announcing today that its ambitious science-based targets have been officially validated, underscoring a strong commitment to sustainability and climate action. This significant milestone aligns with the Group's long-term sustainability strategy, designed to drive positive change across the industry.“As a company, we are determined to lead by example, driving tangible change not only within Rejlers but across our entire supply chain,” says Malin Ljung Eiborn, Rejlers’ Sustainability Director, and continues: “Our science-based targets reflect an internal ambition to

Interim report Q3/2024: Focus on developing existing and new markets

Third quarter January-September · Net sales · Net sales reached SEK 28.4 (35.1)reached SEK 12.6 million.(13.3) · The operating result totaled SEK -38.3 (million. -34.3) million. · The operating · Earnings per share, basic and diluted,result totaled SEK were SEK -0.23 (-0.22).-6.4 (-8.7) · Cash flow from operating activities formillion. the period totaled SEK -40.0 (-37.7) · Earnings per million.share, basic anddiluted, were SEK-0.04 (-0.06). · Cash flow fromoperatingactivities totaled

CLS takes next step towards CE marking in neurosurgery by obtaining ISO certificate according to MDR and completion of study at Skåne University Hospital

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS or the "Company") today announces that the company has received ISO certificate in accordance with the new Medical Device Regulation (MDR) and that the follow-up of patients in the CLS-sponsored clinical study at Skåne University Hospital has now been completed. The company has thus achieved two very important milestones on the way to a market approval of the ClearPoint Prism® Neuro Laser Therapy System in Europe.CLS has obtained ISO certificate in accordance with MDR The change in the new Medical Device Regulation (MDR) places

QLIFE HOLDING AB, Interim Report Q3, July to September 2024

Finally thereFinancial summary – third quarter 2024 · Revenue in the period amounted to kSEK 0 (45). · EBITDA for the period amounted to kSEK –27,151 (-6,660), and net loss kSEK – 28,087 (-8,926). · The total cash flow in the third quarter amounted to kSEK 2,979 (-3,631). · Earnings per share before/after dilution for the quarter amounted to SEK -0.12 (-0.01), calculated on weighted average number of shares in the period. Significant events – third quarter 2024 · On 2. July Qlife announces that it has participated a research trial in the USA for people living with PKU (

Coor extends IFM agreement with Borealis

Coor extends the agreement with Borealis by signing a new 3-year agreement for IFM services. The agreement starts January 1, 2025. The collaboration has also been expanded to include several new services.The extended agreement means that Coor will continue to deliver integrated workplace services and property services to Borealis’ some 1,000 employees at 140 facilities at its Stenungsund site. Borealis produces plastics for power cables, communication cables, pipe systems, automotive components and advanced packaging solutions. Services included in the agreement include property

Financial Calendar 2025

TORM plc expects to issue financial statements and to convene its Annual General Meeting on the following dates in 2025:   06 March 2025   Annual Report 2024 16 April 2025   Annual General Meeting 08 May 2025   First quarter 2025 results 14 August 2025   First six months and second quarter 2025 results 06 November 2025  First nine months and third quarter 2025 results     Contact Mikael Bo Larsen, Head of Investor Relations Tel.: +45 5143 8002                 About TORM TORM is one of the world’s leading carriers of refined oil

ArcticZymes Technologies - Primary insider trading

(Tromsø 06 November 2024) Frank Mathias, Chairman of the Board has on 06 November purchased 7.000 shares in ArcticZymes Technologies ASA for EUR 1.242 per share. Following this transaction holds Mr. Mathias 7.000 shares in the company.Børge Sørvoll, CFO has on 6 November purchased 5.000 shares in ArcticZymes Technoloiges ASA for NOK 14.00 per share. Following this transaction holds Mr. Sørvoll 100.428 shares and 280,000 options in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and

TORM plc Q3/2024 Results, Dividend Distribution, and Financial Outlook 2024

INSIDE INFORMATION “Our performance this quarter remains strong, with fleet-wide freight rates slightly above last year's levels. Despite the expected impact of seasonality, we continued to deliver solid results in the third quarter,” says Jacob Meldgaard. Financial Results In the third quarter of 2024, TORM’s time charter equivalent earnings (TCE) amounted to USD 263.4m (2023, same period: USD 244.4m). TORM realized an adjusted EBITDA of USD 190.9m (2023, same period: USD 186.6m) and a net profit for the period of USD 130.7m (2023, same period: USD 124.3m). In the first nine

GLP-1 and Keytruda steamed ahead in Q3

The report season is in full bloom. In the Big Pharma space, diabetes and obesity remain in focus during the third quarter, while world leader Keytruda enjoys a continued success story. BioStock has taken a closer look at the period.Read the full article at biostock.se : https://www.biostock.se/en/2024/11/glp-1-and-keytruda-steamed-ahead-in-q3/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Expansion in modernized office space at Avenyn

Mullvad VPN, a leading online privacy and security company, is moving up a gear with Wallenstam at Engelbrektsgatan 28. Through an additional rental of 470 square meters, the company’s office space will increase by another floor and comprise around 1,500 square meters in total.The property at Engelbrektsgatan 28 is undergoing an extensive modernization with replacement of the roof, windows, pipes and renovation of the façade and surfaces. In connection with the reconstruction, a holistic approach is also being taken to the technical installations of the premises with new fan rooms and a new

Peab renovates homes in Tromsø

Peab has been commissioned to renovate twelve apartment buildings in Tromsø. The customer is Knausen Bostadsrättsförening and the contract is worth NOK 141 million, about SEK 137 million.The project includes adding insulation and wind proofing facades, replacing windows, balcony and front doors, upgrading entrance halls, building balconies as well as improving the ventilation system and insulating the parking garage. The tenant-owner association consists of 193 apartments spread over 12 buildings. The project has a strong focus on sustainability and reuse, including plans to reuse

Wärtsilä completes fourth round of large-scale fire testing and advances noise mitigation for its energy storage systems

Wärtsilä Corporation, Trade press release, 7 November 2024 at 9 AM EETTechnology group Wärtsilä announces significant advancements in fire safety and acoustic noise reduction for its energy storage systems (ESS), which will enable its customers to stay ahead of regulatory changes while minimising the environmental impact of their projects. These developments, including rigorous large-scale testing and enhanced noise mitigation technologies, further position Wärtsilä as a leader in safe and community-conscious energy solutions. Wärtsilä has recently completed its third and fourth rounds

Neste and Liiga team up to reduce emissions from game travel

Neste Corporation, News, 7 November 2024 Photo: Finland's national ice hockey league teams* will use Neste MY Renewable Diesel for their bus transportation during the 2024–2025 season in Finland. Source: NesteNeste and Finland's national ice hockey league, Liiga, have started a collaboration in which the majority of Liiga teams* will use Neste MY Renewable Diesel™  for their bus transportation during the 2024–2025 season in Finland. With the switch from fossil diesel to Neste MY Renewable

Q3 interim report 2024 – Focus on internal efficiency and product development to drive long-term growth

Q3 Highlights · Continuing integration with newly signed customers in Asia and North America. · Close collaboration with the market to receive feedback from customers to strategically develop and enhance our products. · Internal reorganization to strenghen our teams and become more effective regarding marketing and product development. · Execution of roadmap for upcoming products. Q3 Financial Data · Net Sales of 30.1 MSEK (32.8), down -8.1%. · Adjusted EBITDA amounted to 11.4 MSEK (14.5) with an adjusted EBITDA margin of 37.9% (44.2).* · Adjusted operating

ContextVision publishes Webcast for Q3 2024

Watch CEO Gerald Pötzsch and CFO Richard Hallström present ContextVision’s highlights from Q3 2024 along the financials for the quarter. The Webcast is available on ContextVision’s website following the link below: https://www.contextvision.com/investors/webcast/ For more details, contact ContextVision’s CFO, Richard Hallström at richard.hallstrom@contextvision.com or visit our official website at www.contextvision.com. About ContextVisionContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market

Interim report 1 January–30 September 2024

Stable positive earnings and Arise makes its first sale in energy storage   CEO Comment: In September, Arise made its first transaction in energy storage (BESS) with the sale of the 40 MW Pajkölen project. The transaction means that we are now delivering on our diversification strategy with new technologies and demonstrating our ability to create value by taking advantage of the company’s platform, the synergies between different projects and market knowledge. The project quickly reached the ready-to-build phase and, in addition to the direct sales proceeds, the transaction entails

Change in Pihlajalinna’s Management Team: Seppo Kariniemi appointed as Chief Operating Officer of Public Services

Pihlajalinna Plc       Stock Exchange Release      7 November 2024 at 9:00 a.m. Change in Pihlajalinna’s Management Team: Seppo Kariniemi appointed as Chief Operating Officer of Public Services Seppo Kariniemi has been appointed as the Chief Operating Officer of Pihlajalinna’s Public Services. He has been acting in the role and been part of the Management Team since May 2024. Kariniemi also continues as the Managing director of Pihlajalinna’s and the Wellbeing Services Counties’ joint companies Kuusiolinna Terveys, Jämsän Terveys and Jokilaakson Terveys. "In Pihlajalinna's Public

Relais Group Plc Interim Report January-September 2024 (unaudited): continued profitable growth

Relais Group PlcStock Exchange Release 7 November 2024, 9:00 a.m. EET  This release is a summary of Relais Group's Interim Report January-September 2024. The full report is attached to this release and is available on our website at https://relais.fi/en/investors/. JULY-SEPTEMBER 2024 IN BRIEF  · Net sales totalled EUR 74.9 million (July-September 2023: 70.3), change +7% · Comparable EBITA was EUR 9.2 (8.6) million, change +6% · Comparable EBITA margin was 12.2 (12.3) % · Earnings per share, basic was EUR 0.26 (0.24) · Net cash flow from operations was EUR 4.3 (4.

There are no items matching the current filter
There are no more items matching the current filter
Back to top